Look for Drugs and Conditions

Representative image

Novavax begins phase 2 trial for COVID19-influenza combination and stand-alone influenza vaccines

Maryland-based vaccine developer, Novavax has recently announced that it is beginning the Phase 2 trial for its COVID19-Influenza Combination (CIC) and influenza stand-alone vaccine candidates, which will evaluate the safety and effectiveness of different formulations of the CIC and influenza vaccine candidates in people over 50 years.

Announcing the initiation, President and Chief Executive Officer of Novavax Stanley C. Erck said, “We are encouraged by the initiation of this trial given the positive results shared earlier this year from our Phase 1/2 trial, the first of its kind to evaluate a combined COVID19 and influenza vaccine.”

“We believe that like influenza, COVID19 will also be seasonal moving forward and that there is room in the market for new alternatives to provide better protection against the impact of influenza, particularly in older adults, and to explore the potential to combine this with protection from COVID,” he added.

The company further informed that the randomised, observer-blinded trial will assess a combination of its recombinant protein-based COVID19 vaccine (NVX-CoV2373), quadrivalent influenza vaccine candidate, and patented saponin-based adjuvant.

Primary and secondary objectives of the study are to assess the safety, tolerability, and immune responses to various formulations of the CIC and influenza vaccine candidates, Novavax said.

The trial seeks to confirm the vaccine dosage will enrol 2,300 participants in Australia and New Zealand across multiple Novavax informed in a statement, informing that it expects initial results by mid-2023.

NVX-CoV2373 is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. The vaccine was created using Novavax's recombinant nanoparticle technology to generate antigens derived from the coronavirus spike protein and is formulated with its patented saponin-based adjuvant to enhance the immune response and stimulate high levels of neutralising antibodies.


0 Comments
Be first to post your comments

Post your comment

Related Articles

Ad 5